CTRI/2016/11/007439已完成3 期
Safety and Efficacy Study of Fixed Dose Combination of Three Antidiabetic Drugs in Comparison to Two Antidiabetic Drugs in Patients with Type 2 Diabetes
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 301
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subjects must meet all of the following criteria to be considered for enrollment in the study:
- •1.Male or female patients aged between 18 to 65 years
- •2.Patients diagnosed with type 2 diabetes
- •3.Patients having HbA1c ratio of > 7.5 and < 9
- •4.Patients having BMI of > 23 and < 30 kg/m2
- •5.Patients having Postprandial Blood Glucose (2 hours post- meal) concentration more than 200 mg/dl
- •6.Patients currently on treatment with stable dose of combination of Glibenclamide 5 mg and Metformin 500 mg twice daily for at least 12 weeks before screening.
- •7.Subject or his legally accepted representative is willing to give informed consent
排除标准
- •Subjects meeting any of the following criteria must be excluded from enrollment in the study:
- •1.The patients with the history of serious hypoglycemia shall be excluded.
- •2.Pregnant, lactating women or women of childbearing age who are not using an acceptable method of birth control
- •3.Presence of any clinically relevant disease (e.g. Type I diabetes mellitus, severe cardiovascular disease, significant renal or hepatic impairment, diabetic coma or pre coma, acute or chronic metabolic acidosis including diabetic ketoacidosis and lactic acidosis, severe infection, serious trauma, congestive heart failure that requires treatment etc.)
- •4.Patients having Fasting Blood Glucose concentration more than 270 mg/dl
- •5.Patients received long term insulin therapy (<= 3 days of treatment is allowed)
- •6.Patients who fall into New York Heart Association (NYHA) class III or IV
- •7.Patients receiving Bosentan
- •8.Surgical or medical condition that, in the judgment of the Investigator, could interfere with absorption, distribution, metabolism, or excretion of the drugs to be used
- •9.Current or recent substance abuse, including alcohol
- •10.Refusal or inability to comply with the requirements of the protocol for any reason, including scheduled clinic visits and laboratory tests
- •11.Participation in any experimental drug study within 60 days before screening
- •12.Subjects having intolerance, hypersensitivity or any other contraindication to any of the study products
- •13.Subjects judged unfit for this study by investigator
研究者
相似试验
已完成
3 期
A clinical trial to study the efficacy and safety of combination drugs of chlorthalidone, metoprolol and telmisartan in treatment of high blood pressure with stable coronary artery disease.CTRI/2016/11/007491Sun Pharma Laboratories Limited254
已完成
4 期
Efficacy and Safety Study Tablet ( Irpo- FA®) in Pregnant WomeIron Deficiency & Folic acid Deficiency anemia.Iron deficiency anaemia, unspecified & Folate deficiency anaemia, unspecifiedD-50 & D-5IRCT201610197978N3abiqasim Industries (Pvt) Ltd.50
进行中（未招募）
1 期
Efficacy and Safety of Fixed-Dose Combination atorvastatin/amlodipine/perindopril versus Fixed-Dose Combination of atorvastatin/ amlodipine in Patients with Hypertension and Dyslipidemia.hypertension and dyslipidemiaMedDRA version: 19.0Level: HLTClassification code 10020774Term: Vascular hypertensive disorders NECSystem Organ Class: 100000004866MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2014-005378-12-BGInstitut de Recherche Internationales Servier830
已完成
3 期
A clinical study to evaluate the effects of Fixed Dose Combination of 2 drugs, Indapamide S.R. (1.5 mg) + Amlodipine (5 mg) in patients with high blood pressureCTRI/2010/091/000114Serdia Pharmaceuticals India Pvt Ltd240
尚未招募
不适用
Efficacy and safety of newer SGLT2 and DPP-IV inhibitors, when given in single pill as combinations versus given as separate pills together, in type 2 diabetes on MetformiCTRI/2023/02/049730Jawaharlal Nehru Medical college, Aligarh Muslim University